Please login to the form below

Not currently logged in
Email:
Password:

ClinTec International expands into Turkey

CRO says new office will bolster its presence in the Middle East and North Africa

British contract research organisation (CRO) ClinTec International plans to bolster its existing presence in the Middle East and North Africa with a new office in Istanbul.

The company, which already has bases in the region in Cairo, Egypt, Dubai Health Care City, UAE, and Beirut and Lebanon, said its Turkey office would give its global team access to a new patient population.

Founder and CEO Dr Rabinder Buttar said: "The launch of this new office ... reflects the growing significance of Turkey- and the wider MENA region- to the global clinical research market

"We are delighted to be at the forefront of developing expertise in Turkey and the MENA region as a whole."

Established in 1997, ClinTec has had a presence in Africa for over five years and the Middle East for over seven years, and last year commenced operations in Malawi in a move that strengthened its presence in vaccine development.

21st May 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics